C

Cartography Biosciences

Develops precision immunotherapies targeting antigens

Principal Scientist / Associate Director - Developability & Protein Sciences

Full-TimeUpdated on 10/25/2026
$175k - $215k/yr
Senior, Expert
Master's, PhD
South San Francisco, CA, USA
HybridHybrid role based onsite in South San Francisco, with roughly half of the time at the bench.
Biology & BiotechBioprocess & Biomanufacturing

About the job

Requirements
  • A PhD in protein science, biochemistry, biophysics, chemical or biological engineering, or a related discipline with 5+ years of biopharmaceutical industry experience for Principal Scientist or 8+ years for Associate Director; alternatively, an MS with commensurate additional directly relevant experience.
  • Hands-on experience with bispecific or multispecific antibodies, including analysis of product-related species.
  • Hands-on expertise with biophysical and developability methods, including DSF or DSC, analytical SEC, IEX, HIC, CE-SDS, intact mass, self-association assays such as AC-SINS, and polyspecificity assays such as BVP ELISA or PSR.
  • Developability triage experience in a research or discovery setting, translating biophysical data into candidate-selection decisions.
  • Experience with mammalian transient expression and multi-step antibody purification on FPLC systems such as AKTA or equivalent, including Protein A capture and polishing by IEX, HIC, or mixed-mode chromatography.
  • Experience serving as the protein sciences or developability expert on cross-functional therapeutic project teams, including presenting developability data that shaped a candidate-selection or advancement decision.
  • Ability to lead cross-functional teams without direct authority, including setting priorities, running team meetings, and driving decisions to closure.
  • Experience managing or mentoring scientists.
  • Hands-on experience writing code to analyze data or automate lab workflows, such as Python or R, including use of AI coding assistants such as Claude Code.
Responsibilities
  • Deliver developability and biophysical data for therapeutic programs as candidates advance from hit screening through lead optimization to development-candidate nomination.
  • Own the developability screening cascade, including thermal stability, aggregation, self-association, charge variants, hydrophobicity, polyspecificity, and molecular-integrity assessment.
  • Integrate in silico biophysical-property assessment, including sequence liabilities, surface-patch analysis, and aggregation propensity, with experimental data to prioritize and engineer candidates.
  • Characterize advanced leads and development candidates through stress and forced-degradation studies, PTM mapping such as peptide-mapping LC-MS, and early formulation development.
  • Help define and own developability criteria at each program decision gate and apply them consistently across programs.
  • Expand the throughput, robustness, and technical scope of protein analytics capabilities to support AI/ML-driven antibody engineering.
  • Oversee research-stage protein production from 1 mL to 10 L scale, in house and through external partners, as a service with clear intake, prioritization, turnaround, and quality acceptance of incoming material.
  • Optimize transient production of multi-chain bispecific and multispecific assemblies, including knob-into-hole heterodimers and VHH-containing trispecifics, including plasmid chain-ratio tuning to maximize correctly assembled product.
  • Direct purification strategies that resolve bispecific product-related species from correctly paired heterodimer, using Protein A capture with ion exchange, hydrophobic interaction, mixed-mode, and preparative size-exclusion polishing.
  • Scale plate-based expression and purification, in house and through external partners, to keep pace with screening throughput for the AI/ML-driven antibody-engineering platform.
  • Deliver low-endotoxin, high-monomer material meeting in vivo dosing specifications for mouse pharmacology and non-GLP nonhuman-primate studies.
  • Lead Protein Sciences work on cross-functional therapeutic program teams, bringing developability and manufacturability risk into design and advancement decisions and driving those decisions to closure.
  • As the portfolio grows, lead cross-functional program teams, aligning Antibody Engineering, Pharmacology, and Computational Biology around program goals, timelines, and gate decisions.
  • Communicate data, risks, and recommendations to program teams and leadership, and build alignment across functions on resulting decisions.
  • Manage, mentor, and develop scientists in protein purification and analytics, and set day-to-day practices and priorities for the function.
  • Build data capture, analysis, and automation into team workflows, working closely with team members who develop internal software and AI tools.
Desired Qualifications
  • Experience leading or co-leading a cross-functional therapeutic program team, or serving as deputy to a program lead.
  • Experience using in silico tools to predict antibody developability and biophysical properties.
  • Experience with PTM characterization by peptide-mapping LC-MS and stress and forced-degradation studies.
  • Formulation-development experience, particularly high-concentration (greater than 100 mg/mL) formulations for subcutaneous dosing.
  • Experience with liquid-handling automation and high-throughput purification and characterization.
  • Experience managing outsourced protein production or characterization.
  • Knowledge of T-cell-engaging antibody platforms and a background in oncology or immuno-oncology.
  • Experience building data pipelines, analysis tools, or agentic workflows with AI coding tools.

About the company

C

Cartography Biosciences

View

Cartography Biosciences develops precision cancer immunotherapies. It identifies therapeutic targets by analyzing cancers through antigen expression instead of histology or genetic mutations, enabling therapies that specifically engage tumor cells while aiming to minimize harm to healthy tissue. The company designs and commercializes targeted immunotherapies and seeks druggable targets in cancers that are currently untreatable, striving for treatments that are as safe as they are effective and broadly applicable across tumor cells within a patient. In short, its goal is to deliver precise, safe, and potent cancer treatments by pairing a unique target-identification approach with immunotherapy platforms, and to bring these therapies to healthcare providers and patients through commercialization.

Company Size

51-200

Company Stage

Series B

Total Funding

$124M

Headquarters

Foster City, California

Founded

2020

Get referred to Cartography Biosciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cartography and Pfizer announced up to $865 million in January 2026.
  • Samsung Ventures invested in May 2026, extending runway and signaling strategic interest.
  • Cartography dosed its first patient in 2026, unlocking clinical data in colorectal cancer.

What critics are saying

  • CBI-1214 is Cartography’s first clinical asset; a 2026 failure crushes valuation.
  • Off-tumor toxicity remains the core scientific risk if LY6G6D expression exists in healthy tissue.
  • No commercial revenue and limited disclosed pipeline make Cartography dependent on partner deals.

What makes Cartography Biosciences unique

  • ATLAS and SUMMIT map single-cell antigen expression, targeting tumor-selective biology, not histology.
  • CBI-1214 targets LY6G6D in MSS/MSI-L colorectal cancer, a vast immunotherapy-resistant population.
  • Pfizer, Gilead, and Samsung validated Cartography’s discovery engine in 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options

Growth & Insights and Company News

6 month growth

4%

1 year growth

1%

2 year growth

3%
Business Wire
May 8th, 2026
Cartography Biosciences Announces Strategic Investment From Samsung Ventures to Advance Oncology Pipeline

Cartography Biosciences and Samsung Ventures today announced a strategic investment to support the advancement of Cartography’s differentiated oncology pipel...

AllSci
May 7th, 2026
Cartography Biosciences secures strategic investment from Samsung Ventures for oncology pipeline.

Cartography Biosciences secures strategic investment from Samsung Ventures for oncology pipeline. May 7, 2026 South San Francisco-based Cartography Biosciences has received a strategic equity investment from Samsung Ventures to support the advancement of its oncology pipeline and proprietary antigen discovery platforms. The investment amount was not disclosed. The capital was deployed through the Samsung Life Science Fund, which was established by Samsung Biologics (KRX: 207940.KS), Samsung Bioepis, and Samsung C\&T, and is managed by Samsung Ventures. The fund directs capital toward biopharmaceutical companies working across biologics, gene editing, and AI-enabled therapeutics. No additional participating investors were named. Cartography said the partnership is intended to leverage Samsung's life sciences network alongside the company's own antigen discovery and drug development capabilities. The Samsung investment follows a USD 67 million Series B closed in October 2025, led by Pfizer Ventures, with participation from LG Corp, Amgen Ventures, Finchley Healthcare Ventures, Global BioAccess Fund, and Lotte Holdings CVC. The company's first financing - a combined seed and Series A totaling USD 57 million - was raised in July 2022 and led by 8VC. Cartography's pipeline centers on antibody-based therapies designed to engage the immune system against solid tumors. Its lead candidate, CBI-1214, is a T-cell engager targeting LY6G6D in microsatellite stable and microsatellite instability-low colorectal cancer - a patient population with limited options under current immunotherapy approaches. CBI-1214 entered the clinic in early 2026 and is currently enrolling patients in a Phase I study. The company's broader pipeline, while not fully disclosed in public materials, is built around the same antigen discovery logic and is focused on oncology indications where tumor selectivity represents a clinical differentiator. The platforms underpinning Cartography's pipeline - ATLAS and SUMMIT - are designed to address a persistent challenge in cancer immunotherapy: on-target, off-tumor toxicity arising from the expression of therapeutic targets on healthy tissue. ATLAS generates single-cell resolution maps of antigen expression across both normal human tissues and patient tumors, drawing on a dataset the company describes as spanning hundreds of thousands of cell states. The scientific rationale for this approach is that bulk sequencing methods average gene expression across mixed cell populations and can obscure rare but clinically relevant expression in normal tissues - a resolution gap that single-cell profiling is designed to close. The SUMMIT platform extends this logic by identifying combinations of antigens whose co-expression is restricted to tumor cells, even when individual antigens within the combination are also found on healthy tissue. This AND-gate combinatorial strategy is intended to expand the pool of actionable targets beyond what single-antigen approaches allow. In January 2026, Cartography announced a collaboration with Pfizer under which it will apply ATLAS and SUMMIT to identify tumor-selective antigens in an undisclosed indication. The deal includes up to USD 65 million in upfront and near-term milestone payments, with total potential value reaching USD 865 million. Pfizer Ventures had joined the Series B just months prior, with Michael Baran, Partner at Pfizer Ventures, joining Cartography's board as part of that round. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/

Business Wire
Feb 24th, 2026
Cartography Biosciences doses first patient with CBI-1214 T-cell engager in colorectal cancer trial

Cartography Biosciences has dosed the first patient in a Phase 1 trial of CBI-1214, a T-cell engager targeting LY6G6D for microsatellite stable or microsatellite instability-low colorectal cancer. The South San Francisco-based company developed the therapy using its ATLAS and SUMMIT platforms, which identify tumour-specific targets to reduce off-tumour toxicity. MSS/MSI-L tumours represent approximately 95% of colorectal cancer cases and are largely unresponsive to current immunotherapies. The open-label study will evaluate safety, tolerability, pharmacokinetics and preliminary anti-tumour activity in adults with advanced or metastatic disease. Colorectal cancer is the second leading cause of cancer-related mortality worldwide, with more than 1.9 million new cases diagnosed annually. Five-year survival rates for metastatic cases remain below 15%.

GenomeWeb
Jan 6th, 2026
Cartography Bio, Pfizer Collaborate on Tumor Antigen Discovery Effort

Cartography bio, Pfizer collaborate on tumor antigen discovery effort. NEW YORK - Cartography Biosciences said on Tuesday it will collaborate with Pfizer to use its drug discovery platforms to identify tumor-selective antigens for an undisclosed cancer indication. To read the full story...

Business Wire
Oct 7th, 2025
Cartography Secures $67 Million Series B Financing to Advance Differentiated Oncology Pipeline of Antibody-Based Therapies into the Clinic

Cartography Biosciences, Inc., an oncology company advancing an innovative pipeline of T-cell engaging bispecific and multi-specific antibody therapeutics th...